Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.68 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.45 |
| ▸ | STAMBP | O95630 | 1/20 | 0.45 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909363 | 0.89 | HDAC8 (0.83) | HDAC8HDAC6SLC7A5HDAC2KMT2A | |
| SCHEMBL13702375 | 0.83 | HDAC8 (0.68) | HDAC8HDAC6SLC7A5HDAC2CDK8 | |
| SCHEMBL82080 | 0.81 | HDAC8 (0.71) | HDAC8HDAC6KMT2AMEN1POLB | |
| SCHEMBL1200585 | 0.81 | HDAC8 (0.71) | HDAC8HDAC6SLC7A5KMT2AMEN1 | |
| SCHEMBL162859 | 0.81 | KDM4E (0.68) | HDAC8HDAC6SLC7A5HDAC2KMT2A | |
| SCHEMBL31540297 | 0.81 | HDAC8 (0.71) | HDAC8HDAC6KMT2AMEN1POLB | |
| SCHEMBL29357844 | 0.81 | KDM4E (0.68) | HDAC8HDAC6SLC7A5HDAC2KMT2A | |
| SCHEMBL2422043 | 0.81 | HDAC8 (0.71) | HDAC8HDAC6SLC7A5KMT2AMEN1 | |
| SCHEMBL3297688 | 0.80 | HDAC8 (0.46) | HDAC8HDAC6KMT2AMEN1KDM4E | |
| SCHEMBL165800 | 0.80 | NPSR1 (0.61) | HDAC8HDAC6KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-5597683-A | SHARPNESS, HIGH SPEED | FUJI PHOTO FILM CO., LTD. (JP) | 1997-01-28 | — | — | US | disclosed |
| EP-0501468-B1 | Silver halide color photographic photosensitive materials | FUJI PHOTO FILM CO LTD (JP) | 1996-05-01 | — | — | EP | disclosed |
| EP-0501468-A1 | Silver halide color photographic photosensitive materials | FUJI PHOTO FILM CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | HDAC8 2402/4885HDAC6 939/4885SLC7A5 2596/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | HDAC8 626/4885HDAC6 1048/4885SLC7A5 2052/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | HDAC8 710/4885HDAC6 1199/4885SLC7A5 2647/4885 |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | HDAC8 56/4885HDAC6 704/4885SLC7A5 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.